Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Patients With HER2-Positive Breast Cancer
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
Evaluate the efficacy and safety of treatment with MYOCET® in combination with
Cyclophosphamide and Trastuzumab, 4 cycles, followed by Docetaxel plus Trastuzumab, 4 cycles,
in women with stage II or III breast cancer whose tumour overexpresses the HER2 gene.